Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and stops development of liver cancer and chronic disease caused by hepatitis B. It can cause a long term infection and put people at high risk of liver cancer and cirrhosis that may lead to death. Globally, hepatitis B is one of the major health problems that spreads by mucosal or percutaneous exposure as well as through menstrual, seminal, saliva, and vaginal fluids. Hepatitis B can occur due to sexual transmission, by having contact with sex workers and sex with multiple partners. Transmission of disease may also occur due to reuse of syringes and needles both among persons who inject drugs and in health care settings. Moreover, it may occur during surgical, medical, and dental procedures, and use of razors that are contaminated with infected blood. Infants and young children mostly get chronic hepatitis B.
Hepatitis B Therapeutics Market: Dynamics
Limited access to treatment and diagnosis of hepatitis B in many resource constrained settings and increasing prevalence of hepatitis B infections are likely to drive the global hepatitis B therapeutics market during the forecast period. Rising awareness and increasing affordability are some of the key factors that will increase the rate of diagnosis before a person having advanced liver disease. According to the World Health Organization (WHO), infection of chronic hepatitis B is most common in infants. Rising incidence of hepatitis B infections is a major driver of the market. Less availability of antibiotics in the market and effectiveness of antivirals against hepatitis B infections is likely to propel the market during the forecast period. Prevalence of hepatitis B is increasing steadily across the globe. Medications and treatment options are highly expensive. These are the major drivers of the hepatitis B therapeutics market.
Hepatitis B Therapeutics Market: Segmentation
Based on therapy, the global hepatitis B therapeutics market has been segmented into:
- Chemo Therapy
- Immunosuppressant Therapy
- Nucleoside Analogue
In terms of product type, the global hepatitis B therapeutics market has been segmented into:
- Hepatitis B Vaccine
- Anti-viral Drugs
Based on distribution channel, the global hepatitis B therapeutics market has been segmented into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Hepatitis B Therapeutics Market: Region-wise Outlook
In terms of region, the hepatitis B therapeutics market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominated the hepatitis B therapeutics market owing to the high awareness levels, availability of improved infrastructure, and favorable government initiatives relating to the promotion of hepatitis B therapeutics. Europe is the second largest market for hepatitis B therapeutics driven by rising geriatric population, high rates of chronic infections in Central and Eastern Europe. Prevalence of hepatitis B is the highest in Middle East & Africa where adult population is chronically infected. According to the WHO, it is estimated that 2% to 5% of general population is affected chronically in Asia Pacific. Most people with liver cancer die within diagnosis as there are limited treatment options.
Hepatitis B Therapeutics Market: Key Players
Major players operating in the global hepatitis B therapeutics market are GlaxoSmithKline plc, Bristol-Myers Squibb, Novira Therapeutics, Johnson & Johnson, Abivax SA, F. Hoffmann- La Roche, Novartis AG, and Merck & Co. The increasing competition among key players is likely to drive the global hepatitis B therapeutics market during the forecast period.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.